Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glucose-lowering drug use, glycemic outcomes, and severe hypoglycemia: 18-Year trends in 0·9 million adults with Diabetes in Hong Kong (2002–2019)
Aimin Yang, Hongjiang Wu, Eric S. H. Lau, et al.
The Lancet Regional Health - Western Pacific (2022) Vol. 26, pp. 100509-100509
Open Access | Times Cited: 25

Showing 25 citing articles:

Diabetes in China: epidemiology, pathophysiology and multi-omics
Weiping Jia, Juliana C.N. Chan, Tien Yin Wong, et al.
Nature Metabolism (2025)
Closed Access | Times Cited: 2
Clinical outcomes following discontinuation of metformin in patients with type 2 diabetes and advanced chronic kidney disease in Hong Kong: a territory-wide, retrospective cohort and target trial emulation study
Aimin Yang, Mai Shi, Hongjiang Wu, et al.
EClinicalMedicine (2024) Vol. 71, pp. 102568-102568
Open Access | Times Cited: 9
Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: a prospective cohort study
Aimin Yang, Mai Shi, Eric S. H. Lau, et al.
EClinicalMedicine (2022) Vol. 55, pp. 101751-101751
Open Access | Times Cited: 29
Changes in the use of glucose‐lowering drugs: A Danish nationwide study
Anton Pottegård, Jacob Harbo Andersen, Jens Søndergaard, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 4, pp. 1002-1010
Open Access | Times Cited: 29
Population-Based Clinical Studies Using Routinely Collected Data in Hong Kong, China: A Systematic Review of Trends and Established Local Practices
Derek Wu, Ronald Hang Kin Nam, Keith Sai Kit Leung, et al.
Cardiovascular Innovations and Applications (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 11
Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes-Randomized Controlled Trial (PRISM-RCT) in Chinese patients with young-onset diabetes: design, methods and baseline characteristics
Chun Kwan O, Ying Fan, Baoqi Fan, et al.
BMJ Open Diabetes Research & Care (2024) Vol. 12, Iss. 3, pp. e004120-e004120
Open Access | Times Cited: 4
Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin
Juliana C.N. Chan, Aimin Yang, Natural Chu, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S3, pp. 55-74
Closed Access | Times Cited: 4
Prescribing patterns of glucagon-like peptide-1 receptor agonists in the Swedish capital region—a register-based cross-sectional study
Annica Fors, Tomas Forslund, Anders Sundström, et al.
European Journal of Clinical Pharmacology (2025)
Open Access
Real world evidence of insulin and biosimilar insulin therapy—Opportunities to improve adherence, outcomes and cost‐effectiveness
Aimin Yang, Jiazhou Yu, Johnny T. K. Cheung, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Pharmacokinetics and Pharmacodynamics of Prusogliptin (DBPR108), a Once-Daily Dipeptidyl Peptidase-4 Inhibitor, in Patients with Type 2 Diabetes
Wenfang Liu, Kexu Yang, Kehu Yang, et al.
Clinical Pharmacokinetics (2025)
Open Access
Real-World Treatment Patterns according to Clinical Practice Guidelines in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Korea: Multicenter, Retrospective, Observational Study
Ye Yang, Nam Hoon Kim, Jong Ha Baek, et al.
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 2, pp. 279-289
Open Access | Times Cited: 3
Young-Onset Diabetes in East Asians: From Epidemiology to Precision Medicine
Juliana C.N. Chan, O Chun-Kwan, Andrea O. Y. Luk
Endocrinology and Metabolism (2024) Vol. 39, Iss. 2, pp. 239-254
Open Access | Times Cited: 3
Association of dipeptidyl peptidase‐4 inhibitor initiation at glycated haemoglobin <7.5% with reduced major clinical events mediated by low glycated haemoglobin variability
Johnny T. K. Cheung, Aimin Yang, Hongjiang Wu, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 8, pp. 3339-3351
Open Access | Times Cited: 3
Annual trends in glycemic control and prescribing patterns in diabetic treatment according to age in Japanese patients with type 2 diabetes between 2012 and 2019 (JDDM 71)
Itsuko Miyazawa, Hiroki Yokoyama, Noriharu Yagi, et al.
Diabetes Research and Clinical Practice (2023) Vol. 198, pp. 110599-110599
Closed Access | Times Cited: 9
Trends in elevated waist-to-height ratio and waist circumference in U.S. adults and their associations with cardiometabolic diseases and cancer, 1999–2018
Bo Yang, H. J. Yang, Martin M. H. Wong, et al.
Frontiers in Nutrition (2023) Vol. 10
Open Access | Times Cited: 9
Prusogliptin (DBPR108) monotherapy in treatment‐naïve patients with type 2 diabetes: A randomized, double‐blind, active and placebo‐controlled, phase 3 study
Wei Wang, Xiaohui Guo, Cheng Zhang, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 4, pp. 1321-1332
Open Access | Times Cited: 2
Trends in all-cause and cause-specific mortality in older adults with and without diabetes: A territory-wide analysis in one million older adults in Hong Kong
Aimin Yang, Tingting Chen, Mai Shi, et al.
Diabetes Research and Clinical Practice (2024) Vol. 210, pp. 111618-111618
Closed Access | Times Cited: 2
Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose‐lowering therapies
Anton Pottegård, Jacob Harbo Andersen, Jens Søndergaard, et al.
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 2
Attenuated Risk Association of End-Stage Kidney Disease with Metformin in Type 2 Diabetes with eGFR Categories 1–4
Aimin Yang, Eric S. H. Lau, Hongjiang Wu, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 9, pp. 1140-1140
Open Access | Times Cited: 10
Early treatment with dipeptidyl‐peptidase 4 inhibitors reduces glycaemic variability and delays insulin initiation in type 2 diabetes: A propensity score‐matched cohort study
Johnny T. K. Cheung, Aimin Yang, Hongjiang Wu, et al.
Diabetes/Metabolism Research and Reviews (2023) Vol. 40, Iss. 1
Open Access | Times Cited: 5
Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023
Peter Shane Hamblin, Arul Earnest, Anthony Russell, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 11, pp. 4924-4932
Closed Access | Times Cited: 1
Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study
Chi‐Ho Lee, David Tak Wai Lui, Lung‐Yi Mak, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 574-582
Closed Access | Times Cited: 1
Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors
Mei‐Zhen Wu, Tiew‐Hwa Katherine Teng, Christopher Tze Wei Tsang, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2023) Vol. 10, Iss. 1, pp. 45-52
Open Access | Times Cited: 3
Initiation of sodium-glucose cotransporter-2 inhibitors at lower HbA1c threshold attenuates eGFR decline in type 2 diabetes patients with and without cardiorenal disease: A propensity-matched cohort study
Johnny T. K. Cheung, Aimin Yang, Hongjiang Wu, et al.
Diabetes Research and Clinical Practice (2022) Vol. 195, pp. 110203-110203
Closed Access | Times Cited: 2
New-onset infective endocarditis in diabetic patients receiving SGLT2I, DPP4I and GLP1a: A population-based cohort study
Oscar Hou In Chou, Tianyu Gao, Cheuk To Chung, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top